| 1 |
Nakid-Cordero C, Baron M, Guihot A, et al. Natural killer cells in post-transplant lymphoproliferative disorders[J]. Cancers (Basel), 2021，13(8)：1836.
|
| 2 |
Lamb MG, Rangarajan HG, Tullius BP, et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future[J]. Stem Cell Res Ther, 2021，12(1)：211.
|
| 3 |
Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity[J]. J Leukoc Biol, 2019，105(6)：1319-1329.
|
| 4 |
Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells[J]. Nat Immunol, 2008，9(5)：503-510.
|
| 5 |
Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells[J]. Science, 2011，331(6013)：44-49.
|
| 6 |
Walzer T, Dalod M, Robbins SH, et al. Natural-killer cells and dendritic cells: "l′union fait la force" [J]. Blood, 2005，106(7)：2252-2258.
|
| 7 |
Weizman OE, Adams NM, Schuster IS, et al. ILC1 confer early host protection at initial sites of viral infection[J]. Cell, 2017，171(4)：795-808.
|
| 8 |
Lanier LL. NK cell recognition[J]. Annu Rev Immunol, 2005，23：225-274.
|
| 9 |
Hwang I, Zhang T, Scott JM, et al. Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions[J]. Int Immunol, 2012，24(12)：793-802.
|
| 10 |
Claus M, Meinke S, Bhat R, et al. Regulation of NK cell activity by 2B4, NTB-A and CRACC[J]. Front Biosci, 2008，13：956-965.
|
| 11 |
Rose DL, Reagin KL, Oliva KE, et al. Enhanced generation of influenza-specific tissue resident memory CD8 T cells in NK-depleted mice[J]. Sci Rep, 2021，11(1)：8969.
|
| 12 |
Kildey K, Francis RS, Hultin S, et al. Specialized roles of human natural killer cell subsets in kidney transplant rejection[J]. Front Immunol, 2019，10：1877.
|
| 13 |
Legris T, Picard C, Todorova D, et al. Antibody-dependent NK cell activation is associated with late kidney allograft dysfunction and the complement-independent alloreactive potential of donor-specific antibodies[J]. Front Immunol, 2016，7：288.
|
| 14 |
Koenig A, Mezaache S, Callemeyn J, et al. Missing self-induced activation of NK cells combines with non-complement-fixing donor-specific antibodies to accelerate kidney transplant loss in chronic antibody-mediated rejection[J]. J Am Soc Nephrol, 2021，32(2)：479-494.
|
| 15 |
Hassan N, Eldershaw S, Stephens C, et al. CMV reactivation initiates long-term expansion and differentiation of the NK cell repertoire[J]. Front Immunol, 2022，13：935949.
|
| 16 |
Dębska-Zielkowska J, Moszkowska G, Zieliński M, et al. KIR receptors as key regulators of NK cells activity in health and disease[J]. Cells, 2021，10(7)：1777.
|
| 17 |
Costa-García M, Ataya M, Moraru M, et al. Human cytomegalovirus antigen presentation by HLA-DR＋ NKG2C＋ adaptive NK cells specifically activates polyfunctional effector memory CD4＋ T lymphocytes[J]. Front Immunol, 2019，10：687.
|
| 18 |
Lam JKP, Azzi T, Hui KF, et al. Co-infection of cytomegalovirus and Epstein-Barr virus diminishes the frequency of CD56dimNKG2A＋KIR- NK cells and contributes to suboptimal control of EBV in immunosuppressed children with post-transplant lymphoproliferative disorder[J]. Front Immunol, 2020，11：1231.
|
| 19 |
Aguilar EG, Dunai C, Judge SJ, et al. Activation status dictates the function of unlicensed natural killer cells in mice and humans[J]. Blood Adv, 2021，5(20)：4219-4232.
|
| 20 |
Zafarani A, Taghavi-Farahabadi M, Razizadeh MH, et al. The role of NK cells and their exosomes in graft versus host disease and graft versus leukemia[J]. Stem Cell Rev Rep, 2023，19(1)：26-45.
|
| 21 |
López-Botet M, De Maria A, Muntasell A, et al. Adaptive NK cell response to human cytomegalovirus: facts and open issues[J]. Semin Immunol, 2022，65：101706.
|
| 22 |
Shin BH, Ge S, Mirocha J, et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents[J]. Transplantation, 2014，97(3)：294-300.
|
| 23 |
Si YQ, Bian XK, Lu N, et al. Cyclosporine induces up-regulation of immunoglobulin-like transcripts 3 and 4 expression on and activity of NKL cells[J]. Transplant Proc, 2012，44(5)：1407-1411.
|
| 24 |
Morteau O, Blundell S, Chakera A, et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo[J]. PLoS One, 2010，5(10)：e13294.
|
| 25 |
Eissens DN, Van Der Meer A, Van Cranenbroek B, et al. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype[J]. Am J Transplant, 2010，10(9)：1981-1990.
|
| 26 |
Ohata K, Espinoza JL, Lu X, et al. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen[J]. Biol Blood Marrow Transplant, 2011，17(2)：205-213.
|
| 27 |
Jiang J, Yang M, Yang B, et al. Elevated IL-15 levels in systemic lupus erythematosus: potential pathogenesis insight and therapeutic target[J]. Int Immunopharmacol, 2024 ，142(Pt A)：112973.
|
| 28 |
Krukowski K, Eddy J, Kosik KL, et al. Glucocorticoid dysregulation of natural killer cell function through epigenetic modification[J]. Brain Behav Immun, 2011，25(2)：239-249.
|
| 29 |
Eddy JL, Krukowski K, Janusek L, et al. Glucocorticoids regulate natural killer cell function epigenetically[J]. Cell Immunol, 2014，290(1)：120-130.
|
| 30 |
Wlodarczyk M, Torun A, Zerrouqi A, et al. NK cell degranulation triggered by rituximab identifies potential markers of subpopulations with enhanced cytotoxicity toward malignant B cells[J]. Int J Mol Sci, 2024，25(16)：8980.
|
| 31 |
Dong S, Zhao M, Zhu J, et al. Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma[J]. Front Immunol, 2024，15：1442673.
|
| 32 |
Schiele P, Kolling S, Rosnev S, et al. Flow cytometric assessment of FcγRⅢa-V158F polymorphisms and NK cell mediated ADCC revealed reduced NK cell functionality in colorectal cancer patients[J]. Cells, 2024，14(1)：32.
|
| 33 |
Zhou Y, Wang Y, Liang J, et al. Generation, characterization, and preclinical studies of a novel NKG2A-targeted antibody BRY805 for cancer immunotherapy[J]. Antibodies (Basel), 2024，13(4)：93.
|
| 34 |
Geurts VCM, Voorwerk L, Balduzzi S, et al. Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: results of the MIMOSA trial[J]. Breast, 2023，70：76-81.
|